Compass Therapeutics (NASDAQ:CMPX) Hits New 52-Week High – What’s Next?

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) reached a new 52-week high on Wednesday . The company traded as high as $5.05 and last traded at $4.9650, with a volume of 528037 shares traded. The stock had previously closed at $4.63.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Lifesci Capital assumed coverage on shares of Compass Therapeutics in a research report on Monday, October 6th. They issued an “outperform” rating and a $10.00 target price for the company. Wall Street Zen upgraded Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Guggenheim boosted their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, October 8th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.90.

Compass Therapeutics Price Performance

The stock’s fifty day simple moving average is $3.82 and its 200-day simple moving average is $3.02. The stock has a market cap of $693.47 million, a P/E ratio of -11.12 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CMPX. Creative Planning bought a new position in shares of Compass Therapeutics in the second quarter worth $30,000. Strs Ohio acquired a new stake in Compass Therapeutics in the first quarter worth about $34,000. Apollon Wealth Management LLC bought a new position in Compass Therapeutics in the 3rd quarter valued at about $35,000. Victory Capital Management Inc. grew its position in Compass Therapeutics by 20.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after buying an additional 2,164 shares in the last quarter. Finally, Birchview Capital LP acquired a new position in Compass Therapeutics during the 1st quarter valued at about $46,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.